{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:44:04Z","timestamp":1794584644040,"version":"4.9.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The purpose of this study was to establish an estimating equation to predict the 5-level EQ-5D version (EQ-5D-5L) utility score in patients taking iron preparations for heavy menstrual bleeding (HMB) or anemia and to evaluate whether the presence of nausea or vomiting was a significant predictor of EQ-5D-5L-based quality of life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional survey was conducted to collect EQ-5D-5L utility scores and other patient reported outcomes from 385 patients taking iron preparations for HMB or anemia who were selected from the disease patient panel. Using the utility scores as objective variables, explanatory variable candidates were selected considering correlations, multicollinearity, and clinical validity. Predicting models were constructed using regression-based models (linear model, generalized linear model (GLM), Tobit model). Stepwise regression method was applied for selecting statistically significant (p\u2009&lt;\u20090.05) predictors. Goodness-of-fit of models were assessed by mean absolute error and mean squared error (MSE).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The EQ-5D-5L utility scores (mean\u2009\u00b1\u2009standard deviation) of 96 patients with nausea\/vomiting and 289 patients without nausea\/vomiting were 0.67\u2009\u00b1\u20090.16 and 0.84\u2009\u00b1\u20090.14, respectively (p\u2009&lt;\u20090.001). The presence of nausea\/vomiting was shown to be the most significant factor reducing the utility score in the statistical models using the explanatory variable candidates selected in the study. As the results of the goodness-of-fit test, GLM with the smallest MSE was selected to establish the estimating equation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The estimating equation to predict the EQ-5D-5L utility scores in patients taking iron preparations for HMB or anemia was established. The presence of nausea\/vomiting was found to be a factor significantly reducing utility scores, with a decrement of the value estimated to be -0.117.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>UMIN000045700 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.umin.ac.jp\/ctr\/\">http:\/\/www.umin.ac.jp\/ctr\/<\/jats:ext-link>). Registered on October 11, 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-023-02652-1","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T10:01:53Z","timestamp":1695290513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of nausea\/vomiting on EQ-5D-5L utility scores in patients taking iron preparations for heavy menstrual bleeding or anemia"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3258-4429","authenticated-orcid":false,"given":"Kyoko","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Mitobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Momoeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"2652_CR1","unstructured":"World Health Organization. Anaemia in women and children. https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/anaemia_in_women_and_children. Accessed July 25 2023."},{"key":"2652_CR2","unstructured":"World Health Organization. Global nutrition targets 2025: anaemia policy brief. https:\/\/www.who.int\/publications\/i\/item\/WHO-NMH-NHD-14.4. Accessed July 25 2023."},{"issue":"1","key":"2652_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12325-020-01564-y","volume":"38","author":"D Mansour","year":"2021","unstructured":"Mansour D, Hofmann A, Gemzell-Danielsson K. A review of clinical guidelines on the management of Iron Deficiency and Iron-Deficiency Anemia in women with heavy menstrual bleeding. Adv Ther. 2021;38(1):201\u201325.","journal-title":"Adv Ther"},{"issue":"1","key":"2652_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajog.2023.01.017","volume":"229","author":"G Malcolm","year":"2023","unstructured":"Malcolm G, Munro AE, Mast JM, Powers, Peter A, Kouides, Sarah H, O\u2019Brien T, Richards, et al. The relationship between heavy menstrual bleeding, iron deficiency, and iron deficiency anemia. Am J Obstet Gynecol. 2023;229(1):1\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2652_CR5","doi-asserted-by":"publisher","first-page":"604","DOI":"10.12669\/pjms.323.9799","volume":"32","author":"C Gereklioglu","year":"2016","unstructured":"Gereklioglu C, Asma S, Korur A, Erdogan F, Kut A. Medication adherence to oral iron therapy in patients with iron deficiency anemia. Pak J Med Sci. 2016;32(3):604\u20137.","journal-title":"Pak J Med Sci"},{"issue":"2","key":"2652_CR6","doi-asserted-by":"publisher","first-page":"e0117383","DOI":"10.1371\/journal.pone.0117383","volume":"10","author":"Z Tolkien","year":"2015","unstructured":"Tolkien Z, Stecher L, Mander AP, Pereira DA, Powell JJ. Ferrous sulfate supplementation cuses significant gastrointestinal side-effects in adults: a systematic review and meta analysis. PLoS ONE. 2015;10(2):e0117383.","journal-title":"PLoS ONE"},{"issue":"11","key":"2652_CR7","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3109\/14767058.2011.599080","volume":"24","author":"R Ortiz","year":"2011","unstructured":"Ortiz R, Toblli JE, Romero JD, Monterrosa B, Frer C, Macagno E, Breymann C. Efficacy and safety of oral iron(III) polymaltose complex versus ferrous sulfate in pregnant women with iron-deficiency anemia: a multicenter, randomized, controlled study. J Matern Fetal Neonatal Med. 2011;24(11):1347\u201352.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2652_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2326-11-4","volume":"11","author":"RA Moore","year":"2011","unstructured":"Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011;11:4.","journal-title":"BMC Blood Disord"},{"key":"2652_CR9","unstructured":"Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health. Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council. Ver 3.0. https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf. Accessed July 25 2023."},{"issue":"10","key":"2652_CR10","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s11136-006-0030-z","volume":"15","author":"K Ando","year":"2006","unstructured":"Ando K, Morita S, Higashi T, Fukuhara S, Watanabe S, Park J, Kikuchi M, Kawano K, Wasada I, Hotta T. Health-related quality of life among japanese women with iron-deficiency anemia. Qual Life Res. 2006;15(10):1559\u201363.","journal-title":"Qual Life Res"},{"issue":"7","key":"2652_CR11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/aogs.12394","volume":"93","author":"P Peuranp\u00e4\u00e4","year":"2014","unstructured":"Peuranp\u00e4\u00e4 P, Heli\u00f6vaara-Peippo S, Fraser I, Paavonen J, Hurskainen R. Effects of anemia and iron deficiency on quality of life in women with heavy menstrual bleeding. Acta Obstet Gynecol Scand. 2014;93(7):654\u201360.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"11","key":"2652_CR12","doi-asserted-by":"publisher","first-page":"e0166133","DOI":"10.1371\/journal.pone.0166133","volume":"11","author":"G Bai","year":"2016","unstructured":"Bai G, Korfage IJ, Groen EH, Jaddoe VW, Mautner E, Raat H. Associations between nausea, vomiting, fatigue and health-related quality of life of women in early pregnancy: the Generation R Study. PLoS ONE. 2016;11(11):e0166133.","journal-title":"PLoS ONE"},{"key":"2652_CR13","unstructured":"INTAGE Healthcare Inc. https:\/\/www.intage-healthcare.co.jp\/english\/service\/research\/rx\/patient_mindscape. Accessed July 25 2023."},{"issue":"5","key":"2652_CR14","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jval.2016.03.1834","volume":"19","author":"T Shiroiwa","year":"2016","unstructured":"Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S, Shimozuma K. Comparison of Value Set based on DCE and\/or TTO Data: scoring for EQ-5D-5L Health States in Japan. Value Health. 2016;19(5):648\u201354.","journal-title":"Value Health"},{"issue":"8","key":"2652_CR15","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jval.2021.03.010","volume":"24","author":"T Shiroiwa","year":"2021","unstructured":"Shiroiwa T, Noto S, Fukuda T. Japanese Population norms of EQ-5D-5L and Health Utilities Index Mark 3: disutility catalog by Disease and Symptom in Community settings. Valus Health. 2021;24(8):1193\u2013202.","journal-title":"Valus Health"},{"issue":"1","key":"2652_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40780-022-00239-w","volume":"8","author":"H Fujii","year":"2022","unstructured":"Fujii H, Ueda Y, Hirose C, Ohata K, Sekiya K, Kitahora M, Sadaka S, Yamamoto S, Watanabe D, Kato-Hayashi H, Iihara H, Kobayashi R, Kaburaki M, Matsuhashi N, Takahashi T, Makiyama A, Yoshida K, Hayashi H, Suzuki A. Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy. J Pharm Health Care Sci. 2022;8(1):8.","journal-title":"J Pharm Health Care Sci"},{"issue":"1","key":"2652_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12905-021-01462-7","volume":"21","author":"K Shimamoto","year":"2021","unstructured":"Shimamoto K, Hirano M, Wada-Hiraike O, Goto R, Osuga Y. Examining the association between menstrual symptoms and health-related quality of life among working women in Japan using the EQ-5D. BMC Womens Health. 2021;21(1):325.","journal-title":"BMC Womens Health"},{"issue":"11","key":"2652_CR18","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1007\/s11136-017-1642-1","volume":"26","author":"K Yamada","year":"2017","unstructured":"Yamada K, Kamagata E. Reduction of quality-adjusted life years (QALYs) in patients with premenstrual dysphoric disorder (PMDD). Qual Life Res. 2017;26(11):3069\u201373.","journal-title":"Qual Life Res"},{"key":"2652_CR19","unstructured":"Ministry of Health, Labour and, Welfare. Patient Survey 2017. https:\/\/www.mhlw.go.jp\/toukei\/list\/10-20.html. Accessed July 25 2023."}],"updated-by":[{"DOI":"10.1186\/s12905-023-02689-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000}}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02652-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-023-02652-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02652-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T16:04:28Z","timestamp":1700323468000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-023-02652-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2652"],"URL":"https:\/\/doi.org\/10.1186\/s12905-023-02652-1","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12905-023-02689-2","asserted-by":"object"}]},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12905-023-02689-2","URL":"https:\/\/doi.org\/10.1186\/s12905-023-02689-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics review committee, \u201cNon-Profit Organization MINS Institutional Review Board\u201d on September 16, 2021. This study was conducted after obtaining permission to use the EQ-5D-5L questionnaire from the EuroQol Research Foundation (Agreement Number: 160803). Before this study, electronic informed consent was obtained from all individual participants to participate. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Kyoko Ito, Yuko Mitobe and Ryo Inoue are employee of Torii Pharmaceutical Co., Ltd. Mikio Momoeda received consulting fee from Torii Pharmaceutical Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"505"}}